Companies › Syntara
1 active drug program in 1 registered trial: 1 Phase 2; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PXS-4728A LRRK2 inhibitor | LRRK2 | Phase 2 | REM Sleep Behavior Disorder | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05904717 | PXS-4728A | Phase 2 | REM Sleep Behavior Disorder | Neurology | Sep 2024 |
Neuron23 Aptinyx Bial R&D Investments SHINKEI Therapeutics NeuroTherapia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.